SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-037557
Filing Date
2023-11-08
Accepted
2023-11-08 07:45:18
Documents
86
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q akba-20230930.htm   iXBRL 10-Q 1982920
2 EX-10.3 exhibit103-october2023amen.htm EX-10.3 10664
3 EX-31.1 exhibit311-q32023.htm EX-31.1 10975
4 EX-31.2 exhibit312-q32023.htm EX-31.2 11027
5 EX-32.1 exhibit321-q32023.htm EX-32.1 8951
  Complete submission text file 0001628280-23-037557.txt   9106824

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20230930.xsd EX-101.SCH 81744
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20230930_cal.xml EX-101.CAL 71084
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20230930_def.xml EX-101.DEF 363087
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20230930_lab.xml EX-101.LAB 885536
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20230930_pre.xml EX-101.PRE 579019
80 EXTRACTED XBRL INSTANCE DOCUMENT akba-20230930_htm.xml XML 1077234
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 231386002
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences